BARDA provides CDMO $628m to serve US government

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/C5Media)
(Image: Getty/C5Media)

Related tags: Johnson & johnson, BARDA, Emergent biosolutions, Novavax, Coronavirus, COVID-19

Emergent receives funds to provide manufacturing capabilities to the US government for COVID-19 vaccine candidates.

The funding from the US Biomedical Advanced Research and Development Authority (BARDA) to Emergent BioSolutions arrives as the two partners extend an existing contract.

The contract development and manufacturing organization (CDMO) will now provide its services to the US government for the development of a vaccine for COVID-19. Previously, the contract had covered working together ‘for pandemic preparedness’, which now extends into aiding in the current crisis.

The majority of the $628m (€561m) in funds will be utilized to reserve Emergent’s services for molecule-to-market CDMO services and to commit manufacturing capacity towards COVID-19 programs. The CDMO will be commissioned to provide these services through 2021.

As to which companies will be able to access these services, this will be determined by the US government, depending on the programs it believes to be the most promising.

The rest of the sum, $85.5m, will be spent expanding Emergent’s viral and non-viral drug product fill/finish capacity.

All CDMO services will take place at Emergent’s facilities in the US, located in Baltimore Bayview, Baltimore Camden, and Rockville. The latter two facilities will be the recipients of the funds for expansion.

“Emergent’s landmark partnership with BARDA puts us at the forefront of CDMO collaborations, elevating us to respond to these unprecedented times,”​ said Syed Husain, CDMO business unit head at Emergent.

The CDMO was already at the forefront of a number of leading vaccine candidates, including having partnered with Johnson & Johnson​ and with Novovax, the latter recently announced that it would be able to produce one billion doses in 2021​.

Emergent clarified that the extended partnership with BARDA would include working on additional vaccine candidates to the ones previously referenced.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Fill-Finish Biologics

Fill-Finish Biologics

Curia | 16-May-2022 | Technical / White Paper

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Related suppliers

Follow us


View more